|
|
va recentrer sa force de vente américaine pour soutenir le déploiement national de Sjö™, un test de diagnostic de nouvelle génération pour la détection précoce du syndrome de Goujerot-Sjögren chez les patients souffrant de sécheresse oculaire, et sur la promotion du portefeuille de tests RetnaGene™, incluant RetnaGene™ AMD et RetnaGene™ LR, deux tests génétiques spécialisés pour évaluer le risque pour un individu de progresser jusqu’à une forme avancée de dégénérescence maculaire liée à l’âge (DMLA).
|
|
|
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that Nicox’s subsidiary, Nicox Inc, will focus its US sales force on supporting the national roll-out of Sjö™, an advanced diagnostic panel for the early detection of Sjögren’s syndrome in patients with dry eye, and on promoting the RetnaGene™ portfolio including RetnaGene™ AMD and RetnaGene™ LR, specialized genetic tests which assess an individual’s risk for advanced age-related macular degeneration (AMD). Nicox and Rapid Pathogen Screening (RPS®) have therefore agreed to restructure the terms of their partnership in North America. Effective August 1st, 2014, RPS® will resume responsibility for marketing AdenoPlus®, a point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis, to eye care professionals in North America, as well as two other diagnostic products currently in development. RPS® will pay a royalty on sales to Nicox. Nicox will continue to have rights to commercialize AdenoPlus® and the previously licensed development products in all markets outside of North America.
|
